Vitreous VEGF clearance is increased after vitrectomy

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 4, 2010, Pages 2135-2138

  Lee, Susan S ^a   Ghosn, Corine ^b   Yu, Zhiling ^b   Zacharias, Leandro C ^c   Kao, Henry ^b   Lanni, Carmine ^b   Abdelfattah, Natania ^b   Kuppermann, Baruch ^c   Csaky, Karl G ^d   D'Argenio, David Z ^a   Burke, James A ^b   Hughes, Patrick M ^b   Robinson, Michael R ^b  

^a University of Southern California ^*  (United States)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CILIARY DISK; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RABBIT; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; VITRECTOMY; ANIMAL; HALF LIFE TIME; METABOLISM; RABBIT; VITREOUS BODY;

ANIMALS; AREA UNDER CURVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 77951216656     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3582     Document Type: Article

References (40)

1. Yamamoto T, Hitani K, Tsukahara I, et al. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol. 2003;135:14-19.
2. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007;27:557-566.
3. Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina. 2008;28:410-419.
4. Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy: a theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001;79:435-440.
5. Shimada H, Akaza E, Yuzawa M, Kawashima M. Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2009;50(6):2953-2955.
6. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol. 2001;132:369-377.
7. Terasaki H, Kojima T, Niwa H, et al. Changes in focal macular electroretinograms and foveal thickness after vitrectomy for diabetic macular edema. Invest Ophthalmol Vis Sci. 2003;44:4465-4472.
8. Eckardt H, Ding M, Lind M, Hansen ES, Christensen KS, Hvid I. Recombinant human vascular endothelial growth factor enhances bone healing in an experimental nonunion model. J Bone Joint Surg. 2005;87:1434-1438.
9. Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGFinduced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005;80:249-258.
10. Stefansson E, Landers MB 3rd, Wolbarsht ML. Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Trans Am Ophthalmol Soc. 1981;79:307-334.
11. Stefansson E, Novack RL, Hatchell DL. Vitrectomy prevents retinal hypoxia in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 1990;31:284-289.
12. Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol. 1982; 93:415-417.
13. Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB Jr. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology. 1985;92:1601-1605.
14. Meredith TA. Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime. Trans Am Ophthalmol Soc. 1993;91:653-699.
15. Pearson PA, Hainsworth DP, Ashton P. Clearance and distribution of ciprofloxacin after intravitreal injection. Retina. 1993;13:326-330.
16. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556-560.
17. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686.
18. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004; 138:1046-1048.
19. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144:124-126.
20. Ficker L, Meredith TA, Gardner S, Wilson LA. Cefazolin levels after intravitreal injection: effects of inflammation and surgery. Invest Ophthalmol Vis Sci. 1990;31:502-505.
21. Unal M, Peyman GA, Liang C, et al. Ocular toxicity of intravitreal clarithromycin. Retina. 1999;19:442-446.
22. Macha S, Mitra AK. Ocular pharmacokinetics of cephalosporins using microdialysis. J Ocul Pharmacol Ther. 2001;17:485-498.
23. Shen YC, Wang MY, Wang CY, et al. Clearance of intravitreal voriconazole. Invest Ophthalmol Vis Sci. 2007;48:2238-2241.
24. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007;27:1260-1266.
25. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
26. Kim H, Csaky KG, Chan CC, et al. The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res. 2006;82: 760-766.
27. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114: 855-859.
28. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-512.
29. Fannon M, Forsten-Williams K, Dowd CJ, Freedman DA, Folkman J, Nugent MA. Binding inhibition of angiogenic factors by heparin sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment. FASEB J. 2003;17:902-904.
30. Goes RM, Nader HB, Porcionatto MA, Haddad A, Laicine EM. Chondroitin sulfate proteoglycans are structural renewable constituents of the rabbit vitreous body. Curr Eye Res. 2005;30:405-413.
31. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J. 2006;20:9-22.
32. Jones M, Tussey L, Athanasou N, Jackson DG. Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J Biol Chem. 2000; 275:7964-7974.
33. Stringer SE. The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans. 2006;34:451-453.
34. Robinson CJ, Mulloy B, Gallagher JT, Stringer SE. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. J Biol Chem. 2006;281: 1731-1740.
35. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS. A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol. 2008;2:77.
36. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
37. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584.
38. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445-450.
39. Velez G, Yuan P, Sung C, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol. 2001;119:1518-1524.
40. Atkinson AJ. Introduction to clinical pharmacology. In: Atkinson AJ, Daniels CE, Dedrick R, Grudzinskas CV, Markey SP, eds. Principles of Clinical Pharmacology. San Diego: Academic Press; 2001:1-4.